EGRX Eagle Pharmaceuticals Inc.

59.35
+0.21  (+0%)
Previous Close 59.14
Open 59.04
Price To Book 4.62
Market Cap 811,384,058
Shares 13,671,172
Volume 13,686
Short Ratio
Av. Daily Volume 138,885
Stock charts supplied by TradingView

NewsSee all news

  1. Eagle Pharmaceuticals Commences Dosing in Pilot Study for Novel Estrogen Receptor Antagonist Product Candidate

    --Product has potential to achieve greater inhibition of estrogen receptors and better outcomes for patients with ER-positive breast cancer-- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today

  2. Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare Conference

    Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 31st Annual Piper Jaffray

  3. Eagle Pharmaceuticals Announces Departure of Douglas L. Braunstein from Board of Directors

    Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that Douglas L. Braunstein is stepping down from the Company's Board of Directors, effective November 14, 2019. Mr. Braunstein joined

  4. Eagle Pharmaceuticals Reports Third Quarter 2019 Results

    -- Net loss of $0.17 per basic and diluted share and adjusted non-GAAP net income of $0.27 per basic and $0.26 per diluted share in Q3 2019 -- -- Plan to initiate a clinical trial in December for Eagle's innovative

  5. Eagle Pharmaceuticals Announces Enrollment of Additional Exertional Heat Stroke Patients at the 2019 Hajj Pilgrimage

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today provided an update on the Company's program for RYANODEX® (dantrolene sodium for injectable suspension) for the treatment of exertional heat

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Pivotal trial planned for 2020.
Fulvestrant
Breast cancer
Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.
PEMFEXY,
Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma
CRL issued July 26, 2017. NDA resubmission planned.
Ryanodex
Exertional heat stroke (EHS)
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
EP-3101 (bendamustine RTD)
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product
KANGIO (bivalirudin injection)
Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)
Approved December 24, 2015.
Docetaxel Injection
Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer
Approved July 22, 2014 under priority review.
Ryanodex
Malignant hyperthermia - cancer
sNDA filing due 2H 2020.
Ryanodex
Nerve agent (NA) exposure

Latest News

  1. Eagle Pharmaceuticals Commences Dosing in Pilot Study for Novel Estrogen Receptor Antagonist Product Candidate

    --Product has potential to achieve greater inhibition of estrogen receptors and better outcomes for patients with ER-positive breast cancer-- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today

  2. Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare Conference

    Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 31st Annual Piper Jaffray

  3. Eagle Pharmaceuticals Announces Departure of Douglas L. Braunstein from Board of Directors

    Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that Douglas L. Braunstein is stepping down from the Company's Board of Directors, effective November 14, 2019. Mr. Braunstein joined

  4. Eagle Pharmaceuticals Reports Third Quarter 2019 Results

    -- Net loss of $0.17 per basic and diluted share and adjusted non-GAAP net income of $0.27 per basic and $0.26 per diluted share in Q3 2019 -- -- Plan to initiate a clinical trial in December for Eagle's innovative

  5. Eagle Pharmaceuticals Announces Enrollment of Additional Exertional Heat Stroke Patients at the 2019 Hajj Pilgrimage

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today provided an update on the Company's program for RYANODEX® (dantrolene sodium for injectable suspension) for the treatment of exertional heat

  6. Eagle Pharmaceuticals to Discuss Third Quarter 2019 Financial Results on November 12, 2019

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its 2019 third quarter financial results on Tuesday, November 12, 2019, before the market

  7. Eagle Pharmaceuticals' Japanese Licensing Partner SymBio Announces its Submission of a New Drug Application for TREAKISYM® Ready-To-Dilute Formulation

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited ("SymBio") has submitted a New Drug Application ("NDA") for TREAKISYM

  8. Eagle Pharmaceuticals, Inc. to Present at 2019 Cantor Global Healthcare Conference

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2019 Cantor Global

  9. Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Morgan Stanley 17th Annual